Banner

Antivirals Global Market Report 2023 – By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes), By Type (Branded, Generic), By Application (HIV, Hepatitis, Herpes, Influenza, Other Applications) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : January 2023 | SKU CODE : r725 | Delivery Time: 2-3 business days | Format :


Anti-viral drug therapy refers to drugs that are used for the treatment of viral infections, such as human immunodeficiency virus (HIV), hepatitis, influenza, and novel coronavirus. Antiviral drugs do not kill their target pathogens; instead, they inhibit the development of those viruses. The anti-viral drug establishments are primarily engaged in the manufacturing of DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

The main types of anti-viral drug therapy are branded and generic. The various drug classes involved are DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others that are used for HIV, hepatitis, herpes, influenza, and others. Reverse-transcriptase inhibitors (RTIs) are a type of antiretroviral medication used to treat HIV infection or AIDS, as well as hepatitis B in some cases.

The anti-viral drug therapy market research report is one of a series of new reports from The Business Research Company that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global antivirals market size will grow from $97.14 billion in 2022 to $107.84 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antivirals market size is expected to grow to $156.99 billion in 2027 at a CAGR of 9.8%.

The demand for anti-viral drugs is anticipated to grow at a rapid pace due to the novel coronavirus outbreak. As there are no vaccines and potential treatments for COVID-19, companies are trying to repurpose existing drugs in the fight against the novel coronavirus. The use of certain existing anti-viral drugs for the COVID-19 treatment is contributing to the growth of the anti-viral drugs market. However, if any of these drugs under trial show further promising results in treating the coronavirus infection, the anti-viral market will see further growth.

Increasing public-private funding for life science research globally is expected to drive the growth of the anti-viral drug therapy market. Currently, there are no drugs or vaccines approved for the treatment of COVID-19 disease, however, there are several vaccines and drugs in the pipeline, that are yet to be approved or launched. Governments around the world announced new grant funds for researchers in vaccines, treatment, and diagnostics. In March 2020, the Canadian government announced $214.6 million for coronavirus research. Wellcome and the Gates Foundation announced they are joining forces with the credit card company MasterCard in a $125 million push to speed up the development of drugs for treating COVID-19 infections. Hence increasing public-private funding for life science research will enhance the research and development which drive the growth of the COVID-19 anti-viral drug therapy market.

The emergence of alternative therapies such as naturopathy and homeopathy for the treatment of viral infections is negatively affecting the market. The development of COVID-19 anti-viral drugs involves high R&D costs. The development of COVID-19 anti-viral drugs involves high operating costs and requires a greater capital investment. Due to the high R&D costs involved in drug development, there is a growth in the demand for alternative medicines such as naturopathy and homeopathy. Saikosaponins (A, B2, C, and D), which are naturally occurring triterpene glycosides isolated from medicinal plants such as Bupleurum spp., Heteromorpha spp., and Scrophulariascorodonia, exert antiviral activity against HCV-22E9. Saikosaponins inhibit viral attachment and penetration stages. The marketed drugs would be priced much higher than the actual manufacturing costs. Hence using these naturopathy and homeopathy medicines can restrain the market growth.

Companies in the anti-viral drug therapy market are continuously innovating through technological advancements to develop drugs to treat different viral infections. Biopharmaceutical companies are developing vaccines for the treatment of novel coronavirus. Technological advances in the pharmaceutical sector include the development of nucleic acid vaccines that are DNA- and RNA-based, and which enable the human body to produce vaccine antigens. In March 2020, Applied DNA Sciences’ subsidiary LineaRx and Takis Biotech formed a joint venture to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine. Such initiatives and activities are projected to support market growth to a significant extent.

In February 2020, GeoVax, a US-based pharmaceutical company, and BravoVax, a China-based pharmaceutical company, announced plans to develop a coronavirus cure in the form of a vaccine based on the former’s MVA-VLP vaccine platform. BravoVax will be responsible for testing and manufacturing the vaccine as well as coordinating with the public health and regulatory authorities in China. GeoVax’s Modified Vaccinia Ankara platform enables enhanced expression and stable transgenes during the manufacturing process. Combined with the immunogenicity of Virus-Like Particles (VLPs), the technology enables the production of vaccines. The collaboration between these two companies is to develop a coronavirus vaccine.

Major players in the anti-viral drug therapy market are AbbVie Inc., Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca PLC., Aurobindo Pharma, Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi, Sanofi, Regeneron Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., Novavax, Inc., and BioCryst Pharmaceuticals, Inc.

North America was the largest region in the anti-viral drug therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global antivirals market during the forecast period. The regions covered in the global anti-viral drug therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the anti-viral drug therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The global antivirals market is segmented -

1) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug Classes

2) By Application: HIV, Hepatitis, Herpes, Influenza, and Other Applications

3) By Type: Branded, Generic

    Table Of Contents

    1. Executive Summary

    2. Anti-Viral Drug Therapy Market Characteristics

    3. Anti-Viral Drug Therapy Market Trends And Strategies

    4. Anti-Viral Drug Therapy Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Anti-Viral Drug Therapy Market

    4.2 Ukraine-Russia War Impact On Anti-Viral Drug Therapy Market

    4.3 Impact Of High Inflation On Anti-Viral Drug Therapy Market

    5. Anti-Viral Drug Therapy Market Size And Growth

    5.1. Global Anti-Viral Drug Therapy Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Anti-Viral Drug Therapy Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Anti-Viral Drug Therapy Market Segmentation

    6.1. Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    DNA Polymerase Inhibitors

    Reverse Transcriptase Inhibitors

    Protease Inhibitors

    Neuraminidase Inhibitors

    Other Drug Class

    6.2. Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    HIV

    Hepatitis

    Herpes

    Influenza

    Other Application

    6.3. Global Anti-Viral Drug Therapy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Branded

    Generic

    7. Anti-Viral Drug Therapy Market Regional And Country Analysis

    7.1. Global Anti-Viral Drug Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Anti-Viral Drug Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Anti-Viral Drug Therapy Market

    8.1. Asia-Pacific Anti-Viral Drug Therapy Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Anti-Viral Drug Therapy Market

    9.1. China Anti-Viral Drug Therapy Market Overview

    9.2. China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Anti-Viral Drug Therapy Market

    10.1. India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Anti-Viral Drug Therapy Market

    11.1. Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Anti-Viral Drug Therapy Market

    12.1. Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Anti-Viral Drug Therapy Market

    13.1. Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Anti-Viral Drug Therapy Market

    14.1. South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Anti-Viral Drug Therapy Market

    15.1. Western Europe Anti-Viral Drug Therapy Market Overview

    15.2. Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Anti-Viral Drug Therapy Market

    16.1. UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Anti-Viral Drug Therapy Market

    17.1. Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Anti-Viral Drug Therapy Market

    18.3. France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Anti-Viral Drug Therapy Market

    19.1. Eastern Europe Anti-Viral Drug Therapy Market Overview

    19.2. Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Anti-Viral Drug Therapy Market

    20.1. Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Anti-Viral Drug Therapy Market

    21.1. North America Anti-Viral Drug Therapy Market Overview

    21.2. North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Anti-Viral Drug Therapy Market

    22.1. USA Anti-Viral Drug Therapy Market Overview

    22.2. USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Anti-Viral Drug Therapy Market

    23.1. South America Anti-Viral Drug Therapy Market Overview

    23.2. South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Anti-Viral Drug Therapy Market

    24.1. Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Anti-Viral Drug Therapy Market

    25.1. Middle East Anti-Viral Drug Therapy Market Overview

    25.2. Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Anti-Viral Drug Therapy Market

    26.1. Africa Anti-Viral Drug Therapy Market Overview

    26.2. Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Anti-Viral Drug Therapy Market Competitive Landscape And Company Profiles

    27.1. Anti-Viral Drug Therapy Market Competitive Landscape

    27.2. Anti-Viral Drug Therapy Market Company Profiles

    27.2.1. AbbVie Inc.

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Bristol-Myers-Squibb

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Cipla

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. F. Hoffmann-La Roche Ltd

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Gilead Sciences Inc

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Anti-Viral Drug Therapy Pipeline Analysis

    29. Key Mergers And Acquisitions In The Anti-Viral Drug Therapy Market

    30. Anti-Viral Drug Therapy Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Anti-Viral Drug Therapy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Anti-Viral Drug Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Anti-Viral Drug Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: China, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: India, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: Japan, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: Australia, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: Indonesia, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: South Korea, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Western Europe, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: UK, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Germany, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: France, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Eastern Europe, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Russia, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: North America, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: USA, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: South America, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Brazil, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Middle East, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Africa, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: AbbVie Inc. Financial Performance
  • Table 28: Bristol-Myers-Squibb Financial Performance
  • Table 29: Cipla Financial Performance
  • Table 30: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 31: Gilead Sciences Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Anti-Viral Drug Therapy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Anti-Viral Drug Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Anti-Viral Drug Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: China, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: India, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: Japan, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: Australia, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: Indonesia, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: South Korea, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Western Europe, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: UK, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Germany, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: France, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Eastern Europe, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Russia, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: North America, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: USA, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: South America, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Brazil, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Middle East, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Africa, Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: AbbVie Inc. Financial Performance
  • Figure 28: Bristol-Myers-Squibb Financial Performance
  • Figure 29: Cipla Financial Performance
  • Figure 30: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 31: Gilead Sciences Inc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report